Sort by

Send to

Choose Destination

Search results

Items: 5


A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease.

Sibley CH, Chioato A, Felix S, Colin L, Chakraborty A, Plass N, Rodriguez-Smith J, Brewer C, King K, Zalewski C, Kim HJ, Bishop R, Abrams K, Stone D, Chapelle D, Kost B, Snyder C, Butman JA, Wesley R, Goldbach-Mansky R.

Ann Rheum Dis. 2015 Sep;74(9):1714-9. doi: 10.1136/annrheumdis-2013-204877. Epub 2014 Jun 6.


Bioequivalence of canakinumab liquid pre-filled syringe and reconstituted lyophilized formulations following 150 mg subcutaneous administration: a randomized study in healthy subjects.

Chioato A, Noseda E, Colin L, Matott R, Skerjanec A, Dietz AJ.

Clin Drug Investig. 2013 Nov;33(11):801-8. doi: 10.1007/s40261-013-0127-4.


A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.

Ruperto N, Quartier P, Wulffraat N, Woo P, Ravelli A, Mouy R, Bader-Meunier B, Vastert SJ, Noseda E, D'Ambrosio D, Lecot J, Chakraborty A, Martini A, Chioato A; Paediatric Rheumatology International Clinical Trials Organisation.

Arthritis Rheum. 2012 Feb;64(2):557-67. doi: 10.1002/art.33342.


Influenza and meningococcal vaccinations are effective in healthy subjects treated with the interleukin-1 beta-blocking antibody canakinumab: results of an open-label, parallel group, randomized, single-center study.

Chioato A, Noseda E, Felix SD, Stevens M, Del Giudice G, Fitoussi S, Kleinschmidt A.

Clin Vaccine Immunol. 2010 Dec;17(12):1952-7. doi: 10.1128/CVI.00175-10. Epub 2010 Oct 20.

Supplemental Content

Loading ...
Support Center